Lilly Industries, Inc.

Eli Lilly and Company

Eli Lilly Industries Limited

Robin G Simmonds

William J Ross

John P Verge

William B Jamieson

George J Cullinan

John Joseph Masters

Magnus Wilhelm Walter

Manuel Javier Cases-Thomas

Carlos Lamas-Peteira

Hélène Catherine Eugénie Rudyk

Helen Louise Haughton

George F Rowland

Sivi Ouwerkerk-Mahadevan

Aryl and heteroaryl morpholine derivatives

A conjugate comprising a vinca moiety convalently linked at the 4-position via a group of the formula --OCOXCO-- where X represents a single chemical bond or an optionally substituted C.sub.1-10 chain, to an immunoglobulin or an immunoglobulin fragment. The conjugates are useful in the treatment of cancer.

Immunoglobulin conjugates

Compounds of formula (I) ##STR1## in which n is 1 or 2, R.sup.1 is C.sub.1-4 alkyl, C.sub.1-4 alkoxy, nitro, amino, halo or hydroxy, m is 0, 1 or 2, R.sup.2 is an immunogenic determinant and x is 1 or 2, provided that when n is 1, x is 1 or 2 and there is one diazo moiety at the 3-position or two diazo moieties at the 3- and 5-positions, with respect to the isothiocyanate group, and the hydroxy group is at the 4-position; and provided that when n is 2, x is 1 and the diazo moiety is at the 4-position and the hydroxy groups are at the 3- and 5-positions, are described. The compounds are useful in the preparation of immunoglobulin conjugates for employment in diagnostic techniques.

Compounds and hapten-immunoglobulin conjugates derived from them

Isothiocyanato-azobenzene-sulfonic, arsonic and substituted-glutamic

Novel hydantoin compounds are described of the formula (I): ##STR1## wherein Ar is phenyl optionally substituted by up to three radicals selected from the group comprising C.sub.1-6 alkoxy, halogen, 1,3-dioxol-2-yl, hydroxy C.sub.1-4 alkoxy C.sub.1-4 alkyl, phenyl, hydroxyl, nitrile, C.sub.1-4 haloalkyl, C.sub.1-4 alkyl, C.sub.2-4 alkenyloxy, C.sub.1-4 alkoxycarbonyl or phenoxy optionally substituted by C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy or halogen;

Thenyl hydantoins and anti-asthmatic compositions thereof

Treatment of immediate hypersensitivity diseases with aryl hydantoins

Pharmaceutical formulations are described, which comprise a hydantoin of formula (I): ##STR1## wherein R.sup.1 is C.sub.1-4 alkyl, R.sup.2 is hydrogen or C.sub.1-4 alkyl; or R.sup.1 and R.sup.2 taken together either represent a C.sub.4-6 alkylene group or a group of formula: ##STR2## where R.sup.5 and R.sup.6 independently represent hydrogen or C.sub.1-4 alkyl;

Method of treating asthma with alkyl, alkylidene and alkylene hydantoins

Hydantoin compounds are described of the formula (I) : ##STR1## wherein R.sup.1 is phenyl, C.sub.1-4 hydroxyalkyl or carboxy C.sub.1-4 alkyl and wherein R.sub.2 is C.sub.1-6 alkyl. The compounds are useful in the prophylactic treatment of immediate hypersensitivity diseases including asthma.

Treating immediate hypersensitivity conditions with 3,5-disubstituted

Growing community of inventors

Wokingham, United Kingdom

Robin G Simmonds